{"id":397,"date":"2026-04-06T09:52:28","date_gmt":"2026-04-06T01:52:28","guid":{"rendered":"http:\/\/47.85.58.59\/?p=397"},"modified":"2026-04-06T09:52:28","modified_gmt":"2026-04-06T01:52:28","slug":"literature-analysis-if-45-8-advanced-car-t-therapy-peptide-screening-services-accelerate-cancer-immunotherapy-rd","status":"publish","type":"post","link":"https:\/\/blog.alphalifetech.com\/397.html","title":{"rendered":"Literature Analysis (IF 45.8) | Advanced CAR-T Therapy & Peptide Screening Services \u2013 Accelerate Cancer Immunotherapy R&D"},"content":{"rendered":"

Literature Analysis (IF 45.8) | Advanced CAR-T Therapy & Peptide Screening Services \u2013 Accelerate Cancer Immunotherapy R&D<\/strong><\/h1>\n

CAR-T therapy harnesses the body\u2019s own T cells to target and destroy cancer cells. In this approach, a patient\u2019s T cells are engineered to express a chimeric antigen receptor (CAR) that recognizes specific antigens on cancer cells, enabling precise killing. Recent breakthroughs, such as the use of deep learning to design binding proteins for peptide\u2013MHC-I complexes, are opening new pathways for even more targeted immunotherapies.<\/p>\n

To develop effective CAR-T treatments, identifying high-affinity binding domains for cancer antigens is essential. While traditional methods rely on animal immunization and antibody screening, peptide screening offers a faster, animal-free alternative.<\/p>\n

Peptide Library Screening \u2013 A Streamlined Workflow<\/strong><\/h2>\n

We support CAR-T and therapeutic discovery with ready-to-use and custom peptide library kits (e.g., random 7-mer, 12-mer, cyclic 7-mer) using phage display technology. Our process includes:<\/p>\n

Library Construction<\/strong><\/h2>\n

Random peptide sequences are cloned into phage coat proteins (e.g., M13 pIII\/pVIII), creating a physical link between the displayed peptide and its DNA.<\/p>\n

Affinity Screening (Biopanning)<\/strong><\/h2>\n

Binding<\/strong><\/h3>\n

Target molecules are immobilized, and the phage library is introduced.<\/p>\n

Washing<\/strong><\/h3>\n

Weakly bound phages are removed.<\/p>\n

Elution<\/strong><\/h3>\n

Specifically bound phages are recovered.<\/p>\n

Amplification<\/strong><\/h3>\n

Eluted phages are amplified in E. coli for enrichment.<\/p>\n

Iterative Rounds<\/strong><\/h2>\n

Typically 3\u20135 rounds are performed to enrich high-affinity binders.<\/p>\n

Identification & Analysis<\/strong><\/h2>\n

Binding Validation<\/strong><\/h2>\n

Positive clones are confirmed via phage ELISA.<\/p>\n

DNA Sequencing<\/strong><\/h2>\n

Peptide sequences are determined.<\/p>\n

Affinity Analysis<\/strong><\/h2>\n

Binding strength is measured using SPR, ELISA, or similar.<\/p>\n

This efficient pipeline helps researchers rapidly discover protein ligands, enzyme substrates, and highly specific binding peptides\u2014accelerating the development of next-generation CAR-T therapies and biologics.<\/p>\n

Read More<\/strong><\/a>!<\/p>\n

Alpha Lifetech<\/strong><\/a>\u00a0has extensive expertise in\u00a0peptide library construction<\/a><\/strong>\u00a0and\u00a0screening services<\/a><\/strong>. In addition to our existing peptide libraries (such as random 7-mer, 12-mer, cyclic 7-mer, and M13\/T7 phage libraries), we offer\u00a0customized peptide library design<\/a>\u00a0<\/strong>and\u00a0screening services<\/a><\/strong>\u00a0tailored to specific experimental needs. We are also continuously exploring downstream applications for identified peptides to create more possibilities for our clients.<\/p>\n","protected":false},"excerpt":{"rendered":"

Literature Analysis (IF 45.8) | Advanced CAR-T Therapy … <\/p>\n","protected":false},"author":1,"featured_media":379,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"slim_seo":{"title":"Literature Analysis (IF 45.8) | Advanced CAR-T Therapy & Peptide Screening Services \u2013 Accelerate Cancer Immunotherapy R&D - Alpha Lifetech","description":"Literature Analysis (IF 45.8) | Advanced CAR-T Therapy & Peptide Screening Services \u2013 Accelerate Cancer Immunotherapy R&D CAR-T therapy harnesses the bo"},"footnotes":""},"categories":[7],"tags":[],"class_list":["post-397","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-targeting-ligands"],"_links":{"self":[{"href":"https:\/\/blog.alphalifetech.com\/wp-json\/wp\/v2\/posts\/397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.alphalifetech.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.alphalifetech.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/wp-json\/wp\/v2\/comments?post=397"}],"version-history":[{"count":1,"href":"https:\/\/blog.alphalifetech.com\/wp-json\/wp\/v2\/posts\/397\/revisions"}],"predecessor-version":[{"id":398,"href":"https:\/\/blog.alphalifetech.com\/wp-json\/wp\/v2\/posts\/397\/revisions\/398"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/wp-json\/wp\/v2\/media\/379"}],"wp:attachment":[{"href":"https:\/\/blog.alphalifetech.com\/wp-json\/wp\/v2\/media?parent=397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/wp-json\/wp\/v2\/categories?post=397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/wp-json\/wp\/v2\/tags?post=397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}